How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

An ETF allows investors to purchase a diversified portfolio of stocks or bonds in a single transaction. People buy shares in ETFs, and the money is invested toward a specific objective. For example, ...

James has been writing about technology for years but has loved it since the early 90s. While his main areas of expertise are maker tools -- 3D printers, vinyl cutters, paper printers, and laser ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctvjnrt76.5 https ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...